Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Selling, General & Admin	49.23	14.06
Research & Development	109.11	10.46
Operating Expenses	158.34	24.52
Operating Income	-158.34	-24.52
Interest & Investment Income	11.05	3.76
Other Non Operating Income (Expenses)	-1.66	12.29
EBT Excluding Unusual Items	-148.96	-8.46
Pretax Income	-148.96	-329.57
Net Income	-148.96	-329.57
Net Income to Common	-148.96	-329.57
Shares Outstanding (Basic)	0	-
Shares Outstanding (Diluted)	0	-
EPS (Basic)	-7819.98	-
EPS (Diluted)	-7819.98	-
Free Cash Flow	-122.3	-185.35
Free Cash Flow Per Share	-6420.52	-
EBITDA	-158.03	-24.44
D&A For EBITDA	0.31	0.08
EBIT	-158.34	-24.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q